Caricamento...
Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics
With an incidence of 68 new cases per 100,000 people per year, an estimated total number of up to 350,000 new non-small-cell lung cancer (NSCLC) cases are diagnosed each year in the European Union. Up to 10% of NSCLC patients are eligible for therapy with novel ALK (anaplastic lymphoma kinase) inhib...
Salvato in:
| Pubblicato in: | Cancers (Basel) |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5532624/ https://ncbi.nlm.nih.gov/pubmed/28696381 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers9070088 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|